Therma Bright Inc Stock Price, News & Analysis

Therma Bright (TBRIF) is evaluating its manufacturing strategy for Venowave products in response to recent US tariff changes on Chinese-manufactured goods. The company is conducting a comprehensive review of manufacturing options including: complete onshoring to North America (Canada, USA, or Mexico), maintaining Chinese production with tariff mitigation strategies, or implementing a hybrid approach combining both locations.

The decision-making process considers multiple factors beyond costs, including:

• Supply chain resilience
• Production lead times
• Quality control measures
• Intellectual property protection
• Logistics efficiency
• Market access and geopolitical stability

The company continues to work with national distributors to expand Venowave's market presence. The Venowave VW5, which qualifies for Medicare and Medicaid HCPCS code reimbursement under 10 medical indications, is an FDA-designated Durable Medical Equipment device that enhances vascular and lymphatic flow in lower limbs.

Therma Bright Inc (TSXV: THRM) (OTCQB: TBRIF) has secured an exclusive U.S. marketing and distribution contract with Global Wellness Products , a subsidiary of Image Protect, Inc. (OTC Pink: IMTL), for its consumer product devices.

The partnership will initially focus on marketing the InterceptCS cold sore prevention device, followed by the rollout of other products including the Benepod hot-and-cold pain therapy device and TherOZap insect bite therapy device. This strategic move comes after Therma Bright's 2024 focus on promoting their Venowave product following permanent HCPCS code receipt.

The agreement targets the global cold sore treatment market, which was valued at USD$1.02 Billion in 2024 and is projected to reach USD$1.57 billion by 2031, according to Coherent Research.

Therma Bright (TSXV: THRM) (OTCQB: TBRIF) has appointed Steve Raysely to its Advisory Board, bringing over two decades of experience in healthcare and technology. Raysely, known for scaling businesses and building market strategies, specializes in medical device sales, AI-driven healthcare solutions, and strategic partnerships.

The company also announced two debt settlements: First, a proposed settlement of $168,300 through the issuance of 3,366,000 common shares at $0.05 per share, pending TSX Venture Exchange approval. Second, the completion of a previously announced debt settlement of $113,000 through the issuance of 2,825,000 common shares at $0.04 per share, with shares subject to a hold period until May 4, 2025.

Therma Bright (TBRIF) has secured a significant purchase order for 1,750 Venowave VW5 units from DME Authority, a national distributor based in Nashville, Tennessee. The order follows successful pilot trials and a previously signed Letter of Intent (LOI) positioning DME as a 'Premier Distributor Partner'. The purchase order represents potential HCPCS code reimbursements totaling $1,434,212 USD (approximately $2,051,602 CAD).

The company has initiated production with a new manufacturing partner to meet growing demand from their national distribution network. This development comes amid a promising market outlook, with the global compression therapy market valued at $4.18 billion in 2024 and projected to reach $6.72 billion by 2033, representing a CAGR of 7.30%.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) has secured an initial purchase order for 100 Venowave VW5 units from Valor Medical Solutions of San Antonio, Texas, a new national distribution partner. The order, valued at $81,955 USD ($117,952 CAD) in HCPCS code reimbursements, follows successful pilot tests of the reimbursement program.

Valor Medical and its network receive approximately 100 doctor referrals daily for vascular compression therapy solutions, with successful HCPCS code reimbursements typically processed within 30-60 days. The distributor plans to place regular orders every few weeks as they expand awareness of the Venowave VW5 solution.

This development occurs in a growing compression therapy market, valued at $4.18 billion in 2024 and projected to reach $6.72 billion by 2033, with a CAGR of 7.30%.

Therma Bright (TBRIF) has signed a letter of intent with DME Authority for a Venowave distribution program in the US. The agreement outlines plans to establish at least three Premier Distributor Partner contracts, each requiring a minimum $2,000,000 inventory purchase, totaling $6,000,000 in Venowave VW5 devices during H1 2025. An equal inventory purchase commitment is required for H2 2025.

DME Authority will acquire remaining Venowave VW5 inventory from Therma Bright in Q1 2025. The distribution program aims to expand patient access across various healthcare channels. The initiative leverages Venowave's permanent HCPCS code E0683 for Medicare reimbursement. The LOI remains non-binding until a final contract is signed.

Therma Bright (TSXV: THRM) (OTCQB: TBRIF) reports positive initial clinical trial results for the PREVA™ ischemic stroke device developed by its investment partner Inretio. The results were presented at the BRAIN Conference 2024 in London by Dr. Gal Yaniv, Director of Endovascular Neurosurgery from Sheba Medical Center. The first phase of clinical trials showed exceptional outcomes, demonstrating the device's potential to improve stroke care and patient recovery. Inretio's CEO Raviv Vine emphasized the company's mission to save lives through medical innovation. The successful presentation marks a significant milestone as Inretio progresses through its clinical program toward global market entry.

Therma Bright announces successful Medicare and Medicaid HCPCS Level II code reimbursements for its Venowave VW5 device through U.S. distribution partners within 60 days. Out of 110 units deployed in pilot tests since October 1, 2024, 25 units have received full reimbursement through commercial health networks or Medicare/Medicaid.

The Venowave VW5, qualifying for reimbursement under 10 medical indications, is a battery-operated peristaltic pump enhancing vascular and lymphatic flow in lower limbs. The FDA-designated Durable Medical Equipment device operates on a rechargeable battery and allows treatment during activity.

The company has begun discussions regarding sales roadmap and manufacturing schedules with distributors, while terminating previously announced private placement financings from September 27, 2024.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) has announced plans to spin off its Consumer Product Portfolio into a separate publicly traded company. The transaction, expected to complete in the first half of 2025, aims to enhance shareholder value and operational focus. The consumer portfolio will include TheroZap insect bite therapy device, InterceptCS cold sore prevention system, Benepod pain relief device, and AcuVid Covid-19 rapid antigen test. Shareholders will receive pro-rata distribution of shares in the new company. The AGM has been deferred until June 30, 2025, to align with the spin-off approval process.